新股太難了,昨日上市今日破發,打新收益壓縮五成,科創板新股不敗將成歷史
作者:範璐媛
來源: 數據寶
久日新材和昊海生科今日開盤破發,成為科創板首兩隻破發股。
兩股雙雙破發
運行108天后,科創板破發一幕上演。今天開盤,科創板第一高價股昊海生科低開1.48%,開盤價較發行價下跌0.78%,成為科創板首隻破發個股。
昊海生科10月30日在科創板掛牌上市。公司主營業務為生物醫用材料的研發、生產和銷售,涉及眼科、整形美容與創面護理、骨科、防粘連及止血四大核心領域。2019年前三季度公司分別實現營業收入和淨利潤11.45億元和2.51億元,淨利潤同比下滑10.04%。

隨後,昨日上市的久日新材低開低走,股價最低下探至66.01元,較發行價下跌1%。公司主營業務為系列光引發劑的研發、生產和銷售。今年前三季度實現營業收入和淨利潤10.58億元,同比增長37.27%,實現淨利潤2.31億元,同比增長86.67%。
值得一提的是,久日新材在上市首日僅收穫6.42%的漲幅,創下了科創板新股上市首日最低紀錄。

截至上午收盤,兩隻個股股價均有所回升,午盤小幅收於發行價以上。此外,傑普特、天準科技和新光光電的最新價較發行價的漲幅已不足10%。
理性來看,科創板破發是新股發行市場化改革的必由之路,是市場逐步迴歸理性的結果,在美歐港等發達市場,新股破發均是常態,打新不敗將成為歷史。
打新收益縮水五成
隨着市場漸趨理性,近期科創板打新收益出現大幅下滑。截至當前,科創板10月以來上市的17只新股上市首日平均漲幅78%,比10月前上市的新股的上市首日平均收益155%縮水了五成。
當前上市的50只科創板個股中,9股上市首日漲幅小於50%,均為10月30日之後上市的新股。久日新材上市首日漲幅僅有6.42%,寶蘭德、奧福環保上市首日收益均不到30%。

不過,雖然打新收益率下滑,一級市場的打新熱情卻絲毫不減。本月上市的10只新股網上平均中籤率僅有0.045%,而此前,除中國通號外其餘科創板新股網上平均中籤率為0.05%。
九成個股上市次日至今股價下滑
雖然科創板個股上市以來平均收益達到了75%,但與首日普漲的行情相比,上次次日後個股走勢普遍較弱。截至上午收盤,91%的創板個股上市次日至今股價下跌,僅南微醫學、樂鑫科技、安恆信息和沃爾德四股上漲。申聯生物和晶晨股份最新價較上市首日收盤價跌幅超過50%,22股較上市以來最高價腰斬。

其中,南微醫學上市以來累計上漲241%,上市次日以來上漲61%,漲幅均為50只科創板個股中最高,也是當前當前科創板個股中所有均線均呈多頭排列的個股,股價在近期再創新高。
南微醫學主要從事微創醫療器械研發、製造和銷售。2019年前三季度公司營收和淨利潤分別同增41%和39%,業績表現優異。與此同時,南微醫學是唯一一家前十大流通股東悉數為機構投資者,且出現險資的科創板企業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.